• Phase 1/2a Trial Testing VBI-1901 in Glioblastoma Mulitforme Doses First Patient
  • Providence Cancer Institute, Nanobiotix Partner for Preclinical Study of NBTXR3 in Pancreatic Cancer
  • Incysus Seeks OK to Begin Phase 1 Trial of Gamma-delta T-cell Immunotherapy for Glioblastoma
  • Inovio and Parker Institute to Collaborate on Bladder Cancer Immunotherapies
  • Certain Types of Gut Bacteria May Increase Immunotherapy’s Effectiveness in Treating Melanoma, Study Finds
  • FDA Grants Breakthrough Therapy Status to Lenvima-Keytruda Combo for Advanced Kidney Cancer
  • Lycera Starts Phase 1b Trial of Non-small Cell Lung Cancer Combo Therapy
  • Initial Safety Review Supports Expansion of MAGE-A10 SPEAR T-Cell Triple Tumor Phase 1 Trial
  • Targovax’s Cancer Immunotherapy TG02 Is Safe, Initial Trial Review Shows
  • Japan Approves Keytruda for Patients with Advanced Urothelial Carcinoma
  • First Patient Dosed in Phase 3 Trial of BeiGene’s Therapy Candidate for Advanced Liver Cancer
  • Opdivo Approved to Prevent Recurrence in Advanced Melanoma Patients